-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the improvement of residents' disposable income, the advancement of medical technology, and the continuous growth of market demand, the immune disease treatment drug market is showing a rapid growth trend in recent years
.
Some market research reports predict that in 2022, the global immunotherapy market will expand from US$61.
5 billion in 2015 to US$74.
2 billion, which may account for half of tumor treatment
.
In addition, according to the forecast report, by 2022, the global immunotherapy market will also form a situation of co-marketing and fierce competition of large-scale original drug varieties
.
But it is worth noting that although the competition will become more and more fierce, with the continuous expansion of the market, the analysis believes that more and more pharmaceutical companies will also begin to increase their layout in this field, and many of them will also choose to cooperate through cooperation.
Join forces
.
It is reported that many companies have recently announced that they will cooperate with other companies in the field of immunotherapy
.
For example, Voyager recently announced that it has reached a licensing and research and development agreement with Novartis.
According to the cooperation agreement, Novartis has the right to evaluate the innovative capsids discovered by the Voyager technology platform, and has the right to fully acquire the development rights of specific capsids for the development of targeted CNS targets.
Point of AAV gene therapy
.
Voyager will receive an up-front payment of $54 million and is eligible to receive milestone payments totaling up to $1.
7 billion
.
Data show that AAV vector is one of the important vectors for delivering gene therapy and other gene medicine products
.
Voyager's AAV capsid discovery platform has identified a series of AAV capsids with unique characteristics that provide better ability to cross the blood-brain barrier and improve transfection in the brain and spinal cord
.
Not long ago, Tianyan Pharmaceutical (ADAG.
US) announced a research cooperation and exclusive technology licensing agreement with Sanofi (SNY.
US), Tianyan Pharmaceutical will lead early research and development activities, using its unique safe antibody SAFEbody technology develops precision masked safe antibodies of the new generation of monoclonal and bispecific antibodies provided by Sanofi, and Sanofi will be responsible for further research and development, product development and commercialization activities in the future
.
It is understood that Tianyan Pharmaceutical is committed to the discovery and development of new cancer immunotherapy based on original antibodies
.
The company is building a highly differentiated product pipeline in-house based on its SAFEbody technology
.
In addition, Junshi Biosciences and Coherus BioSciences also jointly announced recently that the two parties will expand their cooperation in the field of tumor immunity in 2021.
Coherus has started the use of JS006 (an anti-TIGIT monoclonal antibody independently developed by Junshi Biosciences) in the United States and Canada.
Program for licensing options
.
Subject to compliance with applicable laws and conditions as agreed in writing by both parties, Coherus will pay Junshi Biotechnology an upfront payment of $35 million, development, filing and sales milestone payments of up to $255 million, and sales of 18% of net product sales divided into
.
On the whole, the industry believes that with the development of pharmaceutical companies and the continuous entry of capital, more and more immunotherapies and drugs are expected to be approved for marketing, bringing more good news to domestic patients with immune diseases and providing more New, affordable treatment options
.
But at the same time, it should be noted that although the immunotherapy market will continue to develop for the better, and a large number of best-selling drug varieties with over 100 million will be produced, with the expiration of patents and the successive listing of a series of biosimilars, the dual effects of efficacy and price will be achieved.
Under the impact, a large number of immunotherapies will also fall into increasingly fierce market competition
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Some market research reports predict that in 2022, the global immunotherapy market will expand from US$61.
5 billion in 2015 to US$74.
2 billion, which may account for half of tumor treatment
.
In addition, according to the forecast report, by 2022, the global immunotherapy market will also form a situation of co-marketing and fierce competition of large-scale original drug varieties
.
But it is worth noting that although the competition will become more and more fierce, with the continuous expansion of the market, the analysis believes that more and more pharmaceutical companies will also begin to increase their layout in this field, and many of them will also choose to cooperate through cooperation.
Join forces
.
It is reported that many companies have recently announced that they will cooperate with other companies in the field of immunotherapy
.
For example, Voyager recently announced that it has reached a licensing and research and development agreement with Novartis.
According to the cooperation agreement, Novartis has the right to evaluate the innovative capsids discovered by the Voyager technology platform, and has the right to fully acquire the development rights of specific capsids for the development of targeted CNS targets.
Point of AAV gene therapy
.
Voyager will receive an up-front payment of $54 million and is eligible to receive milestone payments totaling up to $1.
7 billion
.
Data show that AAV vector is one of the important vectors for delivering gene therapy and other gene medicine products
.
Voyager's AAV capsid discovery platform has identified a series of AAV capsids with unique characteristics that provide better ability to cross the blood-brain barrier and improve transfection in the brain and spinal cord
.
Not long ago, Tianyan Pharmaceutical (ADAG.
US) announced a research cooperation and exclusive technology licensing agreement with Sanofi (SNY.
US), Tianyan Pharmaceutical will lead early research and development activities, using its unique safe antibody SAFEbody technology develops precision masked safe antibodies of the new generation of monoclonal and bispecific antibodies provided by Sanofi, and Sanofi will be responsible for further research and development, product development and commercialization activities in the future
.
It is understood that Tianyan Pharmaceutical is committed to the discovery and development of new cancer immunotherapy based on original antibodies
.
The company is building a highly differentiated product pipeline in-house based on its SAFEbody technology
.
In addition, Junshi Biosciences and Coherus BioSciences also jointly announced recently that the two parties will expand their cooperation in the field of tumor immunity in 2021.
Coherus has started the use of JS006 (an anti-TIGIT monoclonal antibody independently developed by Junshi Biosciences) in the United States and Canada.
Program for licensing options
.
Subject to compliance with applicable laws and conditions as agreed in writing by both parties, Coherus will pay Junshi Biotechnology an upfront payment of $35 million, development, filing and sales milestone payments of up to $255 million, and sales of 18% of net product sales divided into
.
On the whole, the industry believes that with the development of pharmaceutical companies and the continuous entry of capital, more and more immunotherapies and drugs are expected to be approved for marketing, bringing more good news to domestic patients with immune diseases and providing more New, affordable treatment options
.
But at the same time, it should be noted that although the immunotherapy market will continue to develop for the better, and a large number of best-selling drug varieties with over 100 million will be produced, with the expiration of patents and the successive listing of a series of biosimilars, the dual effects of efficacy and price will be achieved.
Under the impact, a large number of immunotherapies will also fall into increasingly fierce market competition
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
